Dr. Wei Feng, MD

Dr. Feng practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Feng's NPI, 1043277601, was assigned on April 27, 2006. Dr. Feng graduated from Ruprecht Karl University Faculty of Medicine in 1987. Dr. Feng holds California license A51793.

Dr. Feng's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Feng's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Feng is also affiliated with Huntington Hospital. The medical group on file is City of Hope. Dmand AI also links Dr. Feng to 1 more group practice or clinic, 1 other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Feng practices, 3 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Feng's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dr. Feng is board certified in endocrinology, diabetes and metabolism by the American Board of Internal Medicine. Dmand AI has Dr. Feng's licenses on file in 2 states: California and Tennessee.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, high cholesterol, hypercalcemia, obesity, osteoporosis and overactive thyroid among the conditions Dr. Feng treats.

CMS data shows 7,970 Medicare services from Dr. Feng across 8 procedure codes in 2024, for 622 Medicare patients. Medicare paid $262,262 for them.

CMS counts 622 Medicare patients who saw Dr. Feng in 2024. The largest group is 65 to 74, with 274 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Feng's median patient age at 67, with 74% women.

In 2024, Dr. Feng wrote 5,954 Medicare Part D claims for 545 patients. 49% of them were for generic drugs. CMS names the drug for 5,531 of them, across 87 drugs with 11 or more claims each, at $2,044,723 in total drug cost. In 2023, CMS named 5,648 claims across 86 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Feng for performance year 2024, reported as part of a group. Dr. Feng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Feng as offering telehealth.

Dmand AI links 136 papers to Dr. Feng, published from 2001 to 2019. 2016 was the busiest year, with 19. The most frequent topics are Ryanodine Receptor Calcium Release Channel, Calcium and Mice, Inbred C57BL. Dr. Feng has published most often in J Biol Chem. Dr. Feng's most frequent co-authors are Rudruidee Karnchanasorn, MD, Jacque L. Duncan, MD and Ken C. Chiu, MD.

CMS Open Payments shows 475 general payments to Dr. Feng from 51 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 75% of the total. Novo Nordisk Inc paid the most, $3,619. It also lists 1 research payment totaling $125 in 2017.

Dmand AI lists 1 award for Dr. Feng.

Dr. Feng graduated from Ruprecht Karl University Faculty of Medicine in 1987.

Dr. Feng is in network with 16 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.